Foghorn Therapeutics Inc.
FHTX
$5.41
-$0.12-2.17%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 4.77% | 3.43% | -1.99% | 16.78% | 8.14% |
| Total Depreciation and Amortization | 2.90% | 8.67% | 3.82% | -7.33% | -5.27% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.50% | 41.89% | -10.54% | -58.52% | 54.34% |
| Change in Net Operating Assets | 16.85% | -14.35% | -55.12% | 45.82% | -4.40% |
| Cash from Operations | 12.38% | 2.25% | -16.73% | 17.75% | 12.98% |
| Capital Expenditure | 21.43% | 94.15% | -55.02% | -1,717.65% | 83.17% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 15.04% | 29.24% | 137.32% | -239.71% | -166.03% |
| Cash from Investing | 15.08% | 31.90% | 136.35% | -241.11% | -166.34% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 82.73% | 3,375.00% | -99.72% | -98.61% | 8,760.41% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -100.00% | -- |
| Cash from Financing | 82.73% | 3,375.00% | -99.62% | -98.98% | 8,743.70% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 134.89% | 350.54% | 97.26% | -236.14% | 5,611.91% |